Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06661343 · ClinicalTrials.gov registry record · NA
Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM
A NA study, sponsored by Yale University.
- Not yet
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT06661343: Clinical Trial NA study, sponsored by Yale University.
NCT06661343 is a NA study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06661343, a NA study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM). The study will also explore the most effective ways to support participants in continuing their PrEP use over time. The main questions it aims to answer are: * Does the C4 program help participants take PrEP more regularly? * Does adding the 3MV intervention to C4 provide additional support for adherence? Researchers will compare two intervention strategies to see if they result in better PrEP adherence: * C4 Intervention: A program focused on individualized care coordination and addressing structural needs. * C4 + 3MV Intervention: A combination of care coordination with additional behavioral change sessions. Participants will: * Participate in PrEP education and counseling sessions. * Have their PrEP use monitored through dried blood spot (DBS) tests. * Complete questionnaires about their experiences and challenges with PrEP. Receive support sessions tailored to address individual barriers to PrEP adherence.
Primary Outcome
PrEP adherence will be assessed through self-report. Self-reported adherence is measured by doses taken in the past 30 days, with fewer missed doses indicating higher adherence.
Interventions
- BEHAVIORAL C4 Program
- BEHAVIORAL C4 + 3MV Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
What is known before NCT06661343 opens enrollment
NCT06661343 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which C4 Program is the first listed.
NCT06661343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06661343 about?
NCT06661343 is a clinical study titled "Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM". The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM). The study will also explore the most effective ways to support participants in continuing their PrEP use over time...
What is the current status of trial NCT06661343?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2026-08-01. Estimated completion is 2029-06-30.
What interventions are being tested in trial NCT06661343?
The interventions under investigation include: C4 Program (BEHAVIORAL), C4 + 3MV Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06661343?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06661343's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI